Quantcast

Latest Cystic Fibrosis Foundation Stories

2010-12-21 07:00:00

SOUTH PLAINFIELD, N.J., Dec. 21, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) The 48-week study is designed to determine whether ataluren can improve lung function in patients with nmCF. The trial has enrolled 238 patients at 36 sites in North America,...

2010-11-18 14:01:24

An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine. The investigational drug, VX-770, appeared to improve function of what is known as CFTR--the faulty protein responsible for CF. It is among the first compounds being developed for CF that specifically targets the root cause of cystic fibrosis. Patients...

2010-11-15 12:12:44

Researchers at the University of North Carolina at Chapel Hill School of Medicine have demonstrated that the gene mutated in cystic fibrosis not only controls traffic on the chloride highway, but also keeps the sodium highway from being overused. An imbalance of salt and water in patients with cystic fibrosis makes their lungs clog up with sticky mucus that is prone to infection. The cause of the offending imbalance is a well-known genetic error, one that blocks the molecular expressway for...

2010-11-15 07:00:00

SOUTH PLAINFIELD, N.J., Nov. 15, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine. The published data show that treatment with ataluren, an investigational new drug, resulted in statistically significant improvements in the production and function of cystic fibrosis transmembrane...

2010-11-08 11:29:00

Proceeds from holiday DVD sales to support cystic fibrosis research and programs BETHESDA, Md., Nov. 8, 2010 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation announced today that it will partner with CVS/pharmacy and Warner Home Video for the second year to raise critical funds for cystic fibrosis through the sale of classic family movies this holiday season. From now through Dec. 28, 2010, CVS/pharmacy will sell four animated holiday favorites from Warner Home Video, including...

2010-11-04 10:45:00

Academy-Award Winning Movie Director and Oklahoma Native Join the Cystic Fibrosis Foundation to Fight Fatal Disease OKLAHOMA CITY, Nov. 4, 2010 /PRNewswire-USNewswire/ -- The Sooner-Oklahoma City chapter of the Cystic Fibrosis Foundation is pleased to announce that movie director James Cameron and his wife Suzy Amis Cameron will serve as honorary chairs for the 2010 Breath of Life Gala on Nov. 19, 2010. James Cameron is best known for directing "Avatar" and "Titanic," the two...

2010-10-22 11:22:00

BALTIMORE, Oct. 22 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis. The combined results have been presented for the first time at the North American Cystic Fibrosis Conference (NACFC) currently underway in Baltimore. In addition, more results from the second trial (CF302) have been released to supplement the...

2010-10-21 15:05:00

BALTIMORE, Oct. 21 /PRNewswire/ -- A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI® (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year. The results were presented today at the 24th Annual North American Cystic Fibrosis Conference (NACFC) in Baltimore, Maryland,...

2010-10-21 10:30:00

MONMOUTH JUNCTION, N.J., Oct. 21 /PRNewswire/ --Transave, Inc., today reported positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and complete the company's Phase II program for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis...

2010-10-19 08:20:00

Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials BETHESDA, Md., Oct. 19 /PRNewswire-USNewswire/ -- In the largest meeting of its kind, nearly 4,000 doctors, scientists, researchers and caregivers will meet in Baltimore, Md., Oct. 21 -23, 2010, to present the latest information and advancements on cystic fibrosis (CF) drug development, research and care. The conference comes at a critical point in the history of cystic fibrosis, a fatal genetic disease...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related